Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 2

7(77.8%)

Phase 3

1(11.1%)

Phase 1

1(11.1%)

9Total

Phase 2(7)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04114136Phase 2Recruiting

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Role: lead

NCT04080804Phase 2Active Not Recruiting

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Role: lead

NCT06052839Phase 2Recruiting

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

Role: lead

NCT04326257Phase 2Completed

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Role: lead

NCT04157985Phase 3Completed

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Role: lead

NCT04074967Phase 1Active Not Recruiting

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

Role: lead

NCT04369937Phase 2Active Not Recruiting

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

Role: lead

NCT02289209Phase 2Completed

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

Role: lead

NCT02777385Phase 2Completed

Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer

Role: lead

All 9 trials loaded